Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023
print
 

Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides

Download the slide deck

Recommend to a Colleague

Related Posts

Go back to home page